Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Predictive Oncology (NASDAQ:POAI)

Core Insights - Predictive Oncology Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000, allowing its shares to continue trading on the Nasdaq Capital Market under the ticker "POAI" [1] - The company is focusing on a digital asset strategy centered around the Aethir network's native utility token, ATH, as part of its transformational treasury strategy [1][3] Company Overview - Predictive Oncology utilizes artificial intelligence and machine learning to enhance early drug discovery, particularly for cancer treatment, with a platform called PEDAL that predicts drug response with 92% accuracy [2] - The company has access to a biobank of over 150,000 human tumor samples, providing a comprehensive AI-based drug discovery solution [2] Digital Asset Strategy - The company operates a digital asset treasury focused on the ATH token, aiming to create a Strategic Compute Reserve and enhance the Aethir ecosystem's infrastructure for AI [3]